Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$18.49

0.97 (5.54%)

07:18
06/14/19
06/14
07:18
06/14/19
07:18

Kura Oncology says primary endpoint achieved in Phase 2 trial of tipifarnib

Kura Oncology announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma. The results, which will be presented during an oral session at 16:45 CET / 10:45 am ET tomorrow at the European Hematology Association Annual Congress in Amsterdam, demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma as well as non-AITL PTCL. The multi-center, single-arm, open-label Phase 2 trial was designed to determine the efficacy, safety and biomarkers of activity of tipifarnib in patients with relapsed or refractory PTCL. Initially, patients were enrolled without selection in the Phase 2 trial. Based upon molecular characterization of the initial patients, the Phase 2 trial was amended to include two expansion cohorts: 1) patients with AITL, an aggressive form of T-cell lymphoma often characterized by high levels of CXCL12 expression, and 2) patients with PTCL who lack a single nucleotide variation in the 3'-untranslated region of the CXCL12 gene. As of the May 24, 2019 data cutoff, a total of 50 relapsed/refractory PTCL patients with a median number of three prior regimens have been enrolled in all stages of the Phase 2 trial. Key preliminary findings include: The primary efficacy endpoint was achieved in each of the AITL and CXCL12+ expansion cohorts. Sixteen patients were treated in the AITL cohort and 15 in the CXCL12 SNP+ cohort. Among the 11 evaluable patients in the AITL extension cohort, three achieved a complete response and two achieved a partial response, for an objective response rate of 45%. Among the 12 evaluable patients in the CXCL12+ expansion cohort, three achieved a CR and two achieved a PR, for an ORR of 42%. Two of the five responders in the CXCL12+ expansion cohort were AITL patients. When all AITL patients and all PTCL not otherwise specified with available rs2839695 data and absence of this 3'UTR variant enrolled in all portions were taken into account, ORR were 53%/39% for AITL and 20%/18% for CXCL12 SNP+ PTCL-NOS. Thirty-four patients had available gene expression data. Patients with a high ratio of CXCL12 expression to its receptor CXCR4 experienced an ORR of 47% and a clinical benefit rate of 82% with tipifarnib. Next-generation sequencing of 16 AITL patients revealed a high rate of mutation/variation of the killer cell immunoglobulin-like receptors, including KIR3DL2. KIR3DL2 mutation at C336R was concurrent with Q386E and was associated with outcome from tipifarnib therapy. Four of the eight KIR3DL2 C336R/Q386E patients achieved a CR, two achieved a PR and two achieved stable disease for a CR rate of 50%, an ORR of 75% and a clinical benefit rate of 100%. Furthermore, high KIR3DL2 mutant variant allele frequency KIR3DL2 was predictive of complete response to tipifarnib in AITL. Tumors with KIR3DL2 mutations expressed low levels of CXCL5 and its receptor CXCR1 and CXCR2, a potential mechanism of resistance to tipifarnib. Tipifarnib was generally well-tolerated in this Phase 2 trial, with adverse events consistent with its known safety profile. The most frequently observed treatment-related adverse events were hematology-related, including thrombocytopenia, neutropenia, leukopenia, anemia, febrile neutropenia and lymphopenia. Separately, Kura has been evaluating the potential to use CXCL12 pathway biomarkers to enrich for clinical activity in other hematologic malignancies. In addition to AITL, high CXCL12 expression was observed in tumors from other lymphoma patients, including patients with PTCL-NOS, diffuse large B-cell lymphoma and mycosis fungoides, the most common form of cutaneous T-cell lymphoma. Lymphoma patients with CXCL12 reference sequences also appeared to have a higher chance of clinical benefit from tipifarnib treatment. The identification of these CXCL12 reference sequences in responders to tipifarnib across multiple hematologic malignancies will be presented in a poster presentation at 17:30 CET / 11:30 am ET tomorrow at the EHA Annual Congress in Amsterdam.

  • 25

    Jun

KURA Kura Oncology
$18.49

0.97 (5.54%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
01/18/19
PIPR
01/18/19
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology shares remain 'significantly undervalued,' says Piper Jaffray
Kura Oncology today provided evidence that tipifarnib could be active in patients with no abdominal pain and/or nodal/liver met disease, both of which are associated with high CXCL12 expression, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst estimates tipifarnib's opportunity in the HRAS-driven head and neck squamous cell carcinomas opportunity alone is worth $500M-plus in peak sales. However, with the recent data in CXCL12-driven peripheral T-cell lymphomas presented and now potentially pancreatic cancer, these estimates "could be pushed significantly higher over time," Van Buren adds. He continues to believe Kura Oncology shares are "significantly undervalued" and keeps an Overweight rating on the name with a $25 price target.
04/03/19
PIPR
04/03/19
NO CHANGE
PIPR
Overweight
Piper says Kura's potential patient population for tipifarnib keeps growing
After Kura Oncology presented additional data on tipifarnib, a farnesyltransferase inhibitor/HRAS inhibitor that downregulates expression of CXCL12, Piper Jaffray analyst Tyler Van Buren said the number of potential indications for the drug "continues to multiply" as initial clinical data suggest diffuse large B-cell lymphoma and cutaneous T-cell lymphoma patients could benefit from treatment in addition to the already identified cancer indications. The "broad mechanism of tipifarnib is becoming clear" and the potential patient population keeps growing, "well beyond what investors are currently appreciating," according to Van Buren. He keeps an Overweight rating on Kura shares.
05/24/19
SBSH
05/24/19
NO CHANGE
Target $25
SBSH
Buy
Kura Oncology price target raised to $25 from $18 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $25 from $18 saying he believes the data to date support that tipifarnib is likely effective for HRAS-mutant head and neck squamous cell carcinoma. More Phase 2 data in this setting in the second half of 2019 could add further support, Beatty tells investors in a research note. He keeps a Buy rating on Kura Oncology shares.

TODAY'S FREE FLY STORIES

KDP

Keurig Dr Pepper

$28.63

(0.00%)

04:54
06/17/19
06/17
04:54
06/17/19
04:54
Upgrade
Keurig Dr Pepper rating change  »

Keurig Dr Pepper upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$141.64

-0.09 (-0.06%)

04:52
06/17/19
06/17
04:52
06/17/19
04:52
Downgrade
Disney downgraded to In-Line from Outperform at Imperial Capital »

Imperial Capital analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BCYC

Bicycle Therapeutics

$13.00

0.61 (4.92%)

04:48
06/17/19
06/17
04:48
06/17/19
04:48
Initiation
Bicycle Therapeutics initiated  »

Bicycle Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIADF

Kiadis Pharma

$0.00

(0.00%)

04:46
06/17/19
06/17
04:46
06/17/19
04:46
Initiation
Kiadis Pharma initiated  »

Kiadis Pharma initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTT

CatchMark Timber

$10.39

0.015 (0.14%)

04:40
06/17/19
06/17
04:40
06/17/19
04:40
Recommendations
CatchMark Timber analyst commentary  »

CatchMark Timber added to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

03:25
06/17/19
06/17
03:25
06/17/19
03:25
General news
FX Action: USD-CAD has remained buoyant »

FX Action: USD-CAD has…

02:35
06/17/19
06/17
02:35
06/17/19
02:35
General news
FX Update: Narrow ranges have been prevailing »

FX Update: Narrow ranges…

02:30
06/17/19
06/17
02:30
06/17/19
02:30
General news
Asian market Wrap: »

Asian market Wrap:…

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

01:55
06/17/19
06/17
01:55
06/17/19
01:55
Conference/Events
United Technologies participates in a meeting »

United Technologies and…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

DE

Deere

$151.51

0.14 (0.09%)

21:31
06/16/19
06/16
21:31
06/16/19
21:31
Upgrade
Deere rating change at Baird »

Deere upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 17

    Jul

TITN

Titan Machinery

$15.87

-0.6 (-3.64%)

, DE

Deere

$151.51

0.14 (0.09%)

21:30
06/16/19
06/16
21:30
06/16/19
21:30
Upgrade
Titan Machinery, Deere rating change at Baird »

Titan Machinery upgraded…

TITN

Titan Machinery

$15.87

-0.6 (-3.64%)

DE

Deere

$151.51

0.14 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 10

    Jul

  • 17

    Jul

  • 13

    Nov

CTTAY

Continental AG

$0.00

(0.00%)

21:26
06/16/19
06/16
21:26
06/16/19
21:26
Downgrade
Continental AG rating change at JPMorgan »

Continental AG downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YARIY

Yara

$0.00

(0.00%)

20:50
06/16/19
06/16
20:50
06/16/19
20:50
Downgrade
Yara rating change at JPMorgan »

Yara downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTVA

Corteva

$25.20

0.23 (0.92%)

20:49
06/16/19
06/16
20:49
06/16/19
20:49
Upgrade
Corteva rating change at Deutsche Bank »

Corteva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$125.30

0.45 (0.36%)

, SNE

Sony

$51.42

1.735 (3.49%)

19:15
06/16/19
06/16
19:15
06/16/19
19:15
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

UTX

United Technologies

$125.30

0.45 (0.36%)

SNE

Sony

$51.42

1.735 (3.49%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GS

Goldman Sachs

$191.71

0.24 (0.13%)

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

BA

Boeing

$347.19

-1.54 (-0.44%)

RTN

Raytheon

$177.38

0.195 (0.11%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 23

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

GM

General Motors

$35.66

-0.36 (-1.00%)

18:49
06/16/19
06/16
18:49
06/16/19
18:49
Periodicals
GM won't deploy self-driving fleet until safer than human driver, Axios reports »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.